Erythromycin as a prokinetic agent in preterm neonates: a systematic review
Authors:
Open Access
- 1 July 2005
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 90 (4) , F301-f306
Abstract
Background: It often takes several days or even weeks to establish full enteral feeds (FEFs) in preterm, especially extremely low birthweight neonates because of feed intolerance related to gastrointestinal hypomotility. Clinical trials of erythromycin as a prokinetic agent in preterm neonates have reported conflicting results. Aim: To systematically review the efficacy and safety of erythromycin as a prokinetic agent in preterm neonates. Methods: Only randomised controlled trials in preterm neonates (gestation ⩽37 weeks) were considered eligible for inclusion. The primary outcome was the time to reach FEFs of 150 ml/kg/day. The secondary outcomes included the incidence of erythromycin related adverse effects such as diarrhoea, cardiac arrhythmias, and hypertrophic pyloric stenosis. No restrictions were applied on the dose (low: 3–12 mg/kg/day; antimicrobial: ⩾12 mg/kg/6–8 hours) and route (oral or intravenous) and mode (prophylactic or rescue) of administration. The standard methodology for systematic reviews was followed. A subgroup analysis was preplanned based on the dose and mode of drug administration. Results: Seven trials (three prophylaxis, four rescue) with various doses, routes and modes of administration, and durations of erythromycin treatment and different results were found to be eligible for inclusion in the analysis. Meta-analysis could not be performed, as specific data were either inadequate or not available. Conclusion: The conflicting trial results may be explained by differences in dose and route and mode of administration of erythromycin and in gastrointestinal motor responses in the presence of different feeding conditions—for example, fasting v fed state, intermittent v continuous feeds. Gestational and postnatal ages during erythromycin treatment are also important.Keywords
This publication has 58 references indexed in Scilit:
- Erythromycin Fails to Improve Feeding Outcome in Feeding-Intolerant Preterm InfantsJournal of Pediatric Gastroenterology and Nutrition, 2003
- Prediction of Extrauterine Growth Retardation (EUGR) in VVLBW InfantsJournal of Perinatology, 2003
- Extrauterine Growth Restriction Remains a Serious Problem in Prematurely Born NeonatesPediatrics, 2003
- Risk of Infantile Hypertrophic Pyloric Stenosis after Maternal Postnatal Use of MacrolidesScandinavian Journal of Infectious Diseases, 2003
- Two-year outcome of infants weighing 600 grams or less at birth and born 1994 through 1998Obstetrics & Gynecology, 2003
- Infection rates in surgical neonates and infants receiving parenteral nutrition: a five-year prospective studyJournal of Hospital Infection, 2002
- Very Early Exposure to Erythromycin and Infantile Hypertrophic Pyloric StenosisArchives of Pediatrics & Adolescent Medicine, 2002
- Effect of Erythromycin on Gastroduodenal Contractile Activity in Developing NeonatesJournal of Pediatric Gastroenterology and Nutrition, 2002
- Growth Patterns of Extremely Low-Birth-Weight Hospitalized Preterm InfantsJournal of Obstetric, Gynecologic, & Neonatal Nursing, 2002
- The Association of Erythromycin and Infantile Hypertrophic Pyloric StenosisDrug Safety, 2002